Articles in Scholarly Journals [Incomplete List]

1. Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses
   Cancer Immunology, Immunotherapy, vol. 57, no. 9, pp. 1291–1300, 2008
2. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity
   Cancer Immunology, Immunotherapy, vol. 57, no. 11, pp. 1579–1587, 2008
3. Cancer is not just a disease of a tissue: It is a host diseaseHow to reactivate host defense against tumors using conventional therapies of cancer?
   Annales d'Endocrinologie, vol. 69, no. 2, pp. 151–152, 2008
4. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy
   Cell Biology International, vol. 32, no. 9, pp. 1031–1043, 2008
5. Immunogenic cancer cell death: a key-lock paradigm
   Current Opinion in Immunology, vol. 20, no. 5, pp. 504–511, 2008
6. Immunological aspects of cancer chemotherapy
   Nature Reviews Immunology, vol. 8, no. 1, Article ID nri2216, 14 pages, 2008
7. Molecular Interactions between Dying Tumor Cells and the Innate Immune System Determine the Efficacy of Conventional Anticancer Therapies
   Cancer Research, vol. 68, no. 11, pp. 4026–4030, 2008
8. Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells
   Clinical Cancer Research, vol. 14, no. 8, pp. 2413–2420, 2008
9. The anticancer immune response: indispensable for therapeutic success?
   Journal of Clinical Investigation, vol. 118, no. 6, pp. 1991–2001, 2008
10. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Nature Medicine, vol. 13, no. 9, Article ID nm1622, 9 pages, 2007
11. Ecto-calreticulin in immunogenic chemotherapy
    Immunological Reviews, vol. 220, no. 1, pp. 22–34, 2007
12. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
    Immunological Reviews, vol. 220, no. 1, pp. 47–59, 2007
13. Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from "Silent" to Immunogenic
    Cancer Research, vol. 67, no. 17, pp. 7941–7944, 2007
14. Molecular characteristics of immunogenic cancer cell death
    Cell Death and Differentiation, vol. 15, no. 1, Article ID 4402269, 9 pages, 2007
15. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference
    Journal of Molecular Medicine, vol. 85, no. 10, pp. 1069–1076, 2007
16. Links between innate and cognate tumor immunity
    Current Opinion in Immunology, vol. 19, no. 2, pp. 224–231, 2007
17. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
    Cancer Immunology, Immunotherapy, vol. 56, no. 5, pp. 641–648, 2006
18. A novel dendritic cell subset involved in tumor immunosurveillance
    Nature Medicine, vol. 12, no. 2, Article ID nm1356, 5 pages, 2006
19. Calreticulin exposure dictates the immunogenicity of cancer cell death
    Nature Medicine, vol. 13, no. 1, Article ID nm1523, 7 pages, 2006
20. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression
    Immunological Reviews, vol. 214, no. 1, pp. 229–238, 2006
21. Heat Shock Protein 70 Neutralization Exerts Potent Antitumor Effects in Animal Models of Colon Cancer and Melanoma
    Cancer Research, vol. 66, no. 8, pp. 4191–4197, 2006
22. Prise en charge des cancers solides et des hémopathies malignes du sujet âgé : l'oncogériatrie, une discipline en devenir. Seconde partie : traitement des cancers solides (partie 2) et des hémopathies malignes du sujet âgé
    La Revue de Médecine Interne, vol. 26, no. 4, pp. 304–314, 2005
23. Prise en charge des cancers solides et des hémopathies malignes du sujet âgé : l’oncogériatrie une discipline en devenirPremière partie : l’évaluation gériatrique et la prise en charge des cancers solides
    La Revue de Médecine Interne, vol. 26, no. 3, pp. 216–225, 2005
24. Tumor cells convert immature myeloid dendritic cells into TGF- -secreting cells inducing CD4+CD25+ regulatory T cell proliferation
    Journal of Experimental Medicine, vol. 202, no. 7, pp. 919–929, 2005
25. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
    Journal of Experimental Medicine, vol. 202, no. 12, pp. 1691–1701, 2005
26. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor- -dependent manner
    Journal of Experimental Medicine, vol. 202, no. 8, pp. 1075–1085, 2005
27. Acute tubulointerstitial nephritis due to Salmonella typhimurium infection
    European Journal of Internal Medicine, vol. 15, no. 6, pp. 401–401, 2004
28. Increased Immunogenicity of Colon Cancer Cells by Selective Depletion of Cytochrome c
    Cancer Research, vol. 64, no. 8, pp. 2705–2711, 2004
29. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
    European Journal of Immunology, vol. 34, no. 2, pp. 336–344, 2004
30. Microbilles, nanobilles et cytométrie : applications à l'analyse et à la purification cellulaire et moléculaireMicrobeads, nanobeads and cytometry: applications to the analysis and purification of cells and biomolecules
    Pathologie Biologie, vol. 51, no. 7, pp. 418–427, 2003